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TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (BU) X 4 DAYS IN CHIL-
DREN UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (ALLOHSCT) IS PHARMACOKINETICALLY SIMILAR TO Q6
HOUR DOSING IN THE PEDIATRIC POPULATION
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Busulfan (Bu) is often used as part of the conditioning regimen for
pediatric patients undergoing allogeneic (allo) stem cell transplanta-
tion (SCT). Current pediatric dosing recommendations are based on
age and weight, with children 4 years of age or younger receiving
a higher every 6 hour (q6h) dose (1 mg/kg/dose) than children older
than 4 (0.8 mg/kg/dose) (Wall et al, Blood, 2000a). Twice-daily
(q12h) dosing is an attractive alternative to q6h dosing, requiring
less nursing time and less accessing of the patient’s central venous
catheter. Twice-daily dosing is not currently in wide use, however,
as IV Bu has a narrow therapeutic range and there is no published
data confirming that q12h pharmacokinetics (PK) are comparable
to q6h PK. From April 2003 to November 2007, 42 pediatric pa-
tients (age # 21 yrs) with malignant (n 5 16) and nonmalignant (n
5 26) conditions underwent alloSCT (23 unrelated cord blood, 3 re-
lated cord blood, 8 matched unrelated donor peripheral blood or
marrow, 8 matched family donor peripheral blood or marrow)
with preparative regimens including IV Bu q12h x 8 doses (3.2mg/
kg/day, 4 mg/kg/day if age # 4 yrs) and subsequent IV Bu PK anal-
ysis. Patients received phenytoin/fosphenytoin seizure prophylaxis
and FK506/MMF GVHD prophylaxis. PK samples were obtained
at hr 1, 2, 3, 5, 6, 7 and 8 after start of 1st dose. Bu levels were mea-
sured by a GC-MS method on heparinized plasma. PK results were
compared to PK data from pediatric q6h dosing historical controls
derived from the literature (Booth et al, J Clin Pharmacol, 2007)
and from the database of the Toxicology Laboratory of the Hospital
of the University of Pennsylvania. IV Bu q12h clearance (Cl) and vol-
ume of distribution (Vd) point estimates (n 5 38) were similar to
published PK results for q6h dosing in the pediatric population
(q6 vs. q12h Cl [L/h]: 4.04 vs 4.46, respectively; q6 vs. q12h Vd
[L]: 12.8 vs. 13.3, respectively). There was no statistically significant
difference between the steady-state concentrations (Css) (n 5 35)
achieved with q12h dosing when compared to q6h patients well-
matched for age and weight (n5 90) in the University of Pennsylva-
nia database (7376 239 ng/mL vs. 6736 164 ng/mL, p5 0.25; q6h
vs. q12h, respectively). No patients developed VOD. This data sug-
gests that IV Bu q12h in children has a PK profile similar to q6h dos-
ing and is safe, while providing the benefits of reduced nursing time
and less accessing of the patient’s central venous catheter.201
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Hurler syndrome (HS; mucopolysaccharidosis type I) is a lyso-
somal storage disorder caused by a deficiency of iduronidase, with re-
sultant accumulation of glycosaminoglycans in viscera and brain.
Hematopoietic cell transplantation (HCT) has been shown to be
a life-saving measure for children with HS. To decrease the toxicity
of HCT we have offered intravenous iduronidase enzyme replace-
ment therapy (IV ERT) before and after HCT. Twelve children
with HS at a median age of 1.5 years at the time of myeloablativeHCT were eligible. Iduronidase (0.58 mg/kg/dose) was adminis-
tered intravenously in 11–14 weekly doses before HCT and 8 weekly
doses after HCT. The infusions were well tolerated. All patients de-
veloped antibodies to iduronidase, but on day 100 had.90% donor
hematopoiesis, suggesting that ERT prior to HCT is unlikely to al-
ter donor engraftment. All are alive and well, with a median follow-
up of more than 1 year after HCT. Patients with HS, however, also
develop central nervous system (CNS) pathology, and IV-adminis-
tered iduronidase has been shown ineffective in crossing the
blood-brain barrier. Encouraged by the results of intrathecal ERT
(IT ERT) studies in the animal model of HS, we reasoned that clin-
ical investigations incorporating IT ERT, IV ERT, and HCT may
provide increased benefit to HS patients. To date, we have enrolled
3 patients with HS on this IT ERT study. The dose administered is
0.05 mg/kg iduronidase in 3 mL of Elliot’s B solution. Four doses of
drug are administered: the first beginning at the time of IV ERT, the
second just prior to transplantation, the third 100 days post HCT,
and the last 180 days post transplantation. This timing was chosen
to deliver enzyme to the brain until it is anticipated that donor mi-
croglial cells are present in sufficient numbers to deliver enzyme to
the CNS. At present, one patient has received all doses, while the
others continue on study. The 2 patients who were transplanted
are alive and fully engrafted at day 100. Magnetic resonance imaging
and cerebrospinal fluid analysis at the time of IT ERT showed no ev-
idence of brain inflammation. Our data thus demonstrate that mul-
timodal cellular and enzyme therapy in HS is feasible. Importantly,
it affirms the safety of IT ERT, IV ERT, and HCT combination
therapy, and provides a rationale for application of this strategy to
additional HS patients in order to assess fully its impact on long-
term neuropsychological function of HS patients.202
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Hematopoetic stem cell transplantation (HSCT) is used success-
fully in children to treat a variety of disorders. Despite known clin-
ical risk factors, predicting which patients will develop major
complications remains difficult, and transplant-related mortality
approaches 20%. C-reactive protein (CRP) is an acute phase reac-
tant produced by hepatocytes in response to tissue damage, infec-
tion, and inflammation, and it has been shown to be a reliable
marker of systemic inflammation. Studies in adults have demon-
strated that elevated CRP may predict transplant complications,
specifically the development of acute graft-versus-host disease
(aGVHD) and non-relapse mortality (NRM). If similar findings
can be demonstrated in children, it may be possible to identify at-
risk patients who would benefit from more vigilant observation
during their transplant. We enrolled 70 patients (median age, 10
years; range: 3 months–20 years) undergoing allogeneic HSCT at
our institution, drew CRP levels at days 0 and 7, and analyzed
data based on the higher of these values for each patient. We
collected the following demographic information: age, gender,
disease, conditioning regimen and stem cell source. The develop-
ment of complications within 100 days, including severe infection
(defined as gram-negative bacteremia, fungal infections, or other
infections associated with hypotension/sepsis), aGVHD, hepatic
veno-occlusive disease, engraftment failure, relapse and NRM,
was recorded for each patient. Using the Wilcoxon rank sum test,
elevated CRP values were significantly associated with myeloabla-
tive versus reduced-intensity conditioning regimen (p 5 0.003),
malignant versus non-malignant disease (p 5 0.03), subsequent
significant infections (p 5 0.0005), and non-relapse mortality
(p 5 0.02). Conditioning regimen, infection, and non-relapse
mortality remained significant after multivariate analysis (p 5
0.002, p 5 0.0005, and p 5 0.03, respectively). On ROC analysis,
a CRP value .4.35 was 70% sensitive and 72% specific for
development of severe infection, and a CRP value of .7.05 was
72% sensitive and 78% specific for NRM. We did not find a
